Exxon Q4 2025 Earnings Beat Estimates

Exxon Q4 2025 earnings beat consensus with $1.71 EPS and strong cash flow from lower-cost Permian and Guyana production reinforcing investor confidence.

January 30, 2026·2 min read
View all news articles
Flat-vector oil pump and pipeline representing Exxon Q4 2025 earnings beat and cash-flow strength from Permian and Guyana.

KEY TAKEAWAYS

  • Q4 non-GAAP EPS was $1.71, beating $1.68 consensus and revenue topped $82.3 billion.
  • Operating cash flow was $12.7 billion and free cash flow was $5.6 billion.
  • Lower-cost Permian and Guyana production improved unit economics and underpinned funding for growth to 2030.

HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX

Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.

Or subscribe with

Exxon Mobil reported Q4 2025 results on Jan. 30, 2026, with earnings beating estimates as lower-cost production in the Permian Basin and Guyana offset crude-price headwinds and supported strong cash flow.

Q4 Results and Cash Flow

The company said in a press release on Jan. 30, 2026, that it posted non-GAAP earnings of $1.71 a share for the quarter, beating the $1.68 consensus by $0.03. Revenue reached $82.3 billion, surpassing the $81.0 billion forecast. Operating cash flow totaled $12.7 billion, while free cash flow was $5.6 billion. GAAP net income for the quarter was $6.5 billion, and earnings excluding items came to $7.3 billion.

For full-year 2025, GAAP net income declined to $28.8 billion from $33.7 billion in 2024. Non-GAAP earnings excluding items fell to $30.1 billion from $33.5 billion, with full-year non-GAAP EPS at $6.99 compared with $7.79 the prior year.

Production Drivers and Outlook

Exxon attributed the quarter’s outperformance to lower-cost oil production in the Permian Basin and Guyana, which improved unit economics and value capture per barrel and molecule. CEO Darren Woods said, "We're capturing more value from every barrel and molecule we produce and building growth platforms at scale, creating a long runway of profitable growth through 2030 and beyond."

The earnings beat came despite crude oil posting its largest annual price decline since 2020 in 2024. Shares traded near record highs ahead of the report, even as analysts trimmed profit forecasts.

Exxon’s strong cash generation combined with lower-cost barrels provides operating leverage to fund scaled investment and growth platforms toward 2030.

HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX

Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.

Or subscribe with

Read other top news stories

OpenAI Employee Arrested Over Hidden Recording Device

OpenAI Employee Arrested Over Hidden Recording Device

OpenAI employee arrested after a hidden device was discovered; company says models identified installer and found no data loss easing investor risk.

Cipher Digital Convertible Notes Proposal Sends Shares Lower

Cipher Digital Convertible Notes Proposal Sends Shares Lower

Cipher Digital convertible notes proposal would raise $850 million and include a concurrent exchange, raising dilution concerns and pressuring shares.

Character.AI Bankruptcy Draws Disney Interest

Character.AI Bankruptcy Draws Disney Interest

Character.AI bankruptcy starts a Section 363 sale with Disney as stalking-horse and $20 million bid, compressing the auction and shaping recoveries.

AST SpaceMobile Downgrade Sparks Concern

AST SpaceMobile Downgrade Sparks Concern

AST SpaceMobile downgrade after Piper Sandler cut its target, citing launch pace doubts and SpaceX competition, tightening trader positioning.

Six Flags Over Georgia Incident Prompts Ride Closures

Six Flags Over Georgia Incident Prompts Ride Closures

Six Flags Over Georgia incident triggered precautionary coaster closures and state reviews, raising near-term operational risk to attendance and shares.

Johnson & Johnson Q3 2026 Earnings Rise, MedTech Lags

Johnson & Johnson Q3 2026 Earnings Rise, MedTech Lags

Johnson & Johnson Q3 2026 earnings raised guidance to a $101.2 billion sales midpoint while MedTech weakness may force traders to reprice device risk.